Phenotyping an adult zebrafish lamp2 cardiomyopathy model identifies mTOR inhibition as a candidate therapy.

导出 OA

翻译打印收藏纠错

第一作者： Alexey V,Dvornikov

第一单位： Department of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

作者： Alexey V,Dvornikov ^[1] ; Mingmin,Wang ^[2] ; Jingchun,Yang ^[1] ; Ping,Zhu ^[1] ; Tai,Le ^[3] ; Xueying,Lin ^[1] ; Hung,Cao ^[4] ; Xiaolei,Xu ^[5]

作者单位： Department of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. ^[1] Department of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. ^[2] Department of Electrical Engineering and Computer Science, University of California Irvine, CA, USA. ^[3] Department of Electrical Engineering and Computer Science, University of California Irvine, CA, USA; Department of Biomedical Engineering, University of California Irvine, CA, USA. ^[4] Department of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: xu.xiaolei@mayo.edu. ^[5]

关键词 Cardiac contractility Cardiomyopathy Danon disease Disease modeling Hypertrophic remodeling Single myofibril Zebrafish mTOR